header logo image


Page 113«..1020..112113114115..120130..»

Introduction to Genetics – Open Textbook Library

December 13th, 2023 2:38 am

Reviewed by James Langeland, Professor, Kalamazoo College on 1/30/23

Comprehensivenessrating:4see less

This text does what it claims to do. It provides an introductory overview of a broad swath of genetics.

Content Accuracyrating:4

No glaring errors. One could always nitpick any text book.

Relevance/Longevityrating:3

The text is relevant, but not particularly unique in any sense. One could find virtually the same information in any number of genetics textbooks, presented in largely the same way. A major problem here is that the filed is presented more or less historically with many of the experiments and concepts being described having little to no relevance to genetics today. This is a problem with many texts so I do not single this one out.

Clarityrating:4

As with many open source texts, this one suffers from substandard figures, which directly influences clarity. The words on the age are fine, but the adage is true-a picture can be worth a thousand words. The mainstream publishers spent a lot of money on figures and it shows--they can be really good.

Consistencyrating:4

No comments here.

Modularityrating:4

There seem to be appropriate and logical chapter and section breaks.

Organization/Structure/Flowrating:3

The flow is the same as nearly any other genetics textbook. It suffers from a rigid historical framework. Better than most at Muller's morphs however!

Interfacerating:5

No problems here. I do really like the integrated you tube links. I did not dive into the content of those videos (beyond the scope of my review), but the fact that they are there in abundance is a good use of the open source approach.

Grammatical Errorsrating:5

No problems here.

Cultural Relevancerating:3

No comment.

A very timely section on SARS-Cov-2 at the end! Rich with study questions and answers. Genetics is and should be very problem based, so this is good.I appreciate what is being offered here and I understand the market. There is nothing "wrong" with this textbook. There is also no wow factor that would cause me to adopt it at this time.

Read the rest here:
Introduction to Genetics - Open Textbook Library

Read More...

Genetic engineering – DNA Modification, Cloning, Gene Splicing

December 13th, 2023 2:37 am

Most recombinant DNA technology involves the insertion of foreign genes into the plasmids of common laboratory strains of bacteria. Plasmids are small rings of DNA; they are not part of the bacteriums chromosome (the main repository of the organisms genetic information). Nonetheless, they are capable of directing protein synthesis, and, like chromosomal DNA, they are reproduced and passed on to the bacteriums progeny. Thus, by incorporating foreign DNA (for example, a mammalian gene) into a bacterium, researchers can obtain an almost limitless number of copies of the inserted gene. Furthermore, if the inserted gene is operative (i.e., if it directs protein synthesis), the modified bacterium will produce the protein specified by the foreign DNA.

A subsequent generation of genetic engineering techniques that emerged in the early 21st century centred on gene editing. Gene editing, based on a technology known as CRISPR-Cas9, allows researchers to customize a living organisms genetic sequence by making very specific changes to its DNA. Gene editing has a wide array of applications, being used for the genetic modification of crop plants and livestock and of laboratory model organisms (e.g., mice).

The correction of genetic errors associated with disease in animals suggests that gene editing has potential applications in gene therapy for humans. Gene therapy is the introduction of a normal gene into an individuals genome in order to repair a mutation that causes a genetic disease. When a normal gene is inserted into a mutant nucleus, it most likely will integrate into a chromosomal site different from the defective allele; although this may repair the mutation, a new mutation may result if the normal gene integrates into another functional gene. If the normal gene replaces the mutant allele, there is a chance that the transformed cells will proliferate and produce enough normal gene product for the entire body to be restored to the undiseased phenotype.

Genetic engineering has advanced the understanding of many theoretical and practical aspects of gene function and organization. Through recombinant DNA techniques, bacteria have been created that are capable of synthesizing human insulin, human growth hormone, alpha interferon, a hepatitis B vaccine, and other medically useful substances. Plants may be genetically adjusted to enable them to fix nitrogen, and genetic diseases can possibly be corrected by replacing dysfunctional genes with normally functioning genes.

Genes for toxins that kill insects have been introduced in several species of plants, including corn and cotton. Bacterial genes that confer resistance to herbicides also have been introduced into crop plants. Other attempts at the genetic engineering of plants have aimed at improving the nutritional value of the plant.

In 1980 the new microorganisms created by recombinant DNA research were deemed patentable, and in 1986 the U.S. Department of Agriculture approved the sale of the first living genetically altered organisma virus, used as a pseudorabies vaccine, from which a single gene had been cut. Since then several hundred patents have been awarded for genetically altered bacteria and plants. Patents on genetically engineered and genetically modified organisms, particularly crops and other foods, however, were a contentious issue, and they remained so into the first part of the 21st century.

Grains of golden rice, a genetically modified rice (Oryza sativa) that contains beta-carotene.(more)

Special concern has been focused on genetic engineering for fear that it might result in the introduction of unfavourable and possibly dangerous traits into microorganisms that were previously free of theme.g., resistance to antibiotics, production of toxins, or a tendency to cause disease. Indeed, possibilities for misuse of genetic engineering were vast. In particular, there was significant concern about genetically modified organisms, especially modified crops, and their impacts on human and environmental health. For example, genetic manipulation may potentially alter the allergenic properties of crops. In addition, whether some genetically modified crops, such as golden rice, deliver on the promise of improved health benefits was also unclear. The release of genetically modified mosquitoes and other modified organisms into the environment also raised concerns.

In the 21st century, significant progress in the development of gene-editing tools brought new urgency to long-standing discussions about the ethical and social implications surrounding the genetic engineering of humans. The application of gene editing in humans raised significant ethical concerns, particularly regarding its potential use to alter traits such as intelligence and beauty. More practically, some researchers attempted to use gene editing to alter genes in human sperm, which would enable the edited genes to be passed on to subsequent generations, while others sought to alter genes that increase the risk of certain types of cancer, with the aim of reducing cancer risk in offspring. The impacts of gene editing on human genetics, however, were unknown, and regulations to guide its use were largely lacking.

Read more from the original source:
Genetic engineering - DNA Modification, Cloning, Gene Splicing

Read More...

Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 – EIN News

December 13th, 2023 2:37 am

Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027  EIN News

See the article here:
Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News

Read More...

imaware acquires binx health’s consumer testing business, becoming a leader in STI health screening

December 5th, 2023 2:51 am

BOSTON and HOUSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- imaware, a digital health platform company powering home-testing for healthcare brands, and binx health, a molecular diagnostics and consumer testing company, today announced that imaware has acquired binx health’s at-home consumer testing business. The acquisition will expand imaware’s position in the growing market for home-health testing and expand the number of enterprise clients being serviced by imaware. binx health will retain and continue to grow its point-of-care molecular diagnostics business, which is excluded from the imaware transaction.

View original post here:
imaware acquires binx health’s consumer testing business, becoming a leader in STI health screening

Read More...

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

December 5th, 2023 2:51 am

Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023

Read the original:
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

Read More...

Sunshine Biopharma Moves Principal Office to New York City

December 5th, 2023 2:51 am

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous headquarters in Montreal (Canada) at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 (Tel: 514-426-6161). The Company’s email address (info@sunshinebiopharma.com) and URL (www.sunshinebiopharma.com) have not changed.

Read the original post:
Sunshine Biopharma Moves Principal Office to New York City

Read More...

CorMedix Inc. Announces Partnership With The Leapfrog Group

December 5th, 2023 2:51 am

– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog’s Partners Advisory Committee

Read more:
CorMedix Inc. Announces Partnership With The Leapfrog Group

Read More...

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that…

December 5th, 2023 2:51 am

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val

Read more:
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that...

Read More...

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

December 5th, 2023 2:51 am

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications -

Read more:
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Read More...

SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

December 5th, 2023 2:51 am

- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Phase 3 REGAL Trial Without Any Modifications -

See the article here:
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

Read More...

NeuroStar TMS Receives Expanded Regulatory Approval in Japan

December 5th, 2023 2:51 am

Technological advances reduce time and increase efficiency for MDD treatment Technological advances reduce time and increase efficiency for MDD treatment

More here:
NeuroStar TMS Receives Expanded Regulatory Approval in Japan

Read More...

Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of…

December 5th, 2023 2:51 am

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that the State of Tennessee added ZTlido® as a preferred agent to the Medicaid Preferred Drug List effective as of October 1, 2023.1 This change has the potential to improve access to ZTlido® for all eligible patients which includes approximately 1,500,000 adult lives between the ages of 19 to 64.1

Continue reading here:
Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of...

Read More...

Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus

December 5th, 2023 2:51 am

Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it officially executed a Sponsored Research Agreement (SRA) with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.

Read more:
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus

Read More...

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

December 5th, 2023 2:51 am

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of GTB-3650, a 2nd generation nanobody TriKE® for the treatment of patients with CD33+ leukemia, including relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

See more here:
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Read More...

Result of AGM

December 5th, 2023 2:51 am

DXS INTERNATIONAL PLC

More:
Result of AGM

Read More...

RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

December 5th, 2023 2:51 am

PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors.

Read more from the original source:
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors

Read More...

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

December 5th, 2023 2:51 am

CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET.

See the article here:
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Read More...

Celyad announces management change

December 5th, 2023 2:51 am

MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD), a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells, announces that its CEO and managing director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.

Link:
Celyad announces management change

Read More...

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th…

December 5th, 2023 2:51 am

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that it will host a live webcast to review clinical data from the Phase 1 clinical trials of its Bruton’s tyrosine kinase (BTK) degrader programs, NX-5945 and NX-2127, which are being evaluated in patients with relapsed or refractory B cell malignancies, at 8:30 p.m. PST (11:30 p.m. EST) on Monday, December 11, 2023.

Link:
Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th...

Read More...

Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

December 5th, 2023 2:51 am

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgAN to full approval

See the original post here:
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

Read More...

Page 113«..1020..112113114115..120130..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick